Ann: Chairman's Address and CEO update, page-10

Not that anyone reads these posts - but might one day - MSB just saw an intra-day mkt cap jump of some $60 million simply on an FDA designation of one of its applications as a Rare Pediatric Disease (RPD) Designation. Such 'vouchers' are tradeable and have fetched somewhere between $20-$350 million in the past:

https://www.prnewswire.com/news-releases/united-therapeutics-corporation-agrees-to-sell-priority-review-voucher-to-abbvie-for-350-million-300130415.html#:~:text=Upon%20closing%20of%20the%20transaction,treatment%20of%20rare%20pediatric%20diseases.

IP is very difficult to value, but when companies literally trade designations with each other it gives more tangible insight to the potential valuation involved.